The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Reduced oxaliplatin exposure in gastrointestinal cancers: A systematic review and meta-analysis.
 
Wallace Klein Schwengber
No Relationships to Disclose
 
Fares Jamal
No Relationships to Disclose
 
Luís Felipe Leite da Silva
No Relationships to Disclose
 
Abdullah Alsulaiman
No Relationships to Disclose
 
Ayla Kouli
No Relationships to Disclose
 
Oluseyi Abidoye
No Relationships to Disclose
 
Khalid Benkhadra
No Relationships to Disclose
 
Tanios Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Caladrius Biosciences; Caladrius Biosciences; Celularity; Daiichi Sankyo/UCB Japan; Deciphera; Eisai; Eisai; Exact Sciences; Foundation Medicine; Foundation Medicine; Illumina; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Kanaph Therapeutics; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Stemline Therapeutics; Treos Bio; Zai Lab
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - 1Globe Health Institute; AstraZeneca; Exelixis; FibroGen; Imugene; Lilly; Merck (Inst); Pancreatic Cancer Action Network; Replimune; Sun Biopharma; Suzhou Kintor Pharmaceuticals; UpToDate; Xilis
 
Mohamad Sonbol
Honoraria - Novartis
Consulting or Advisory Role - Bayer (Inst); Boehringer Ingelheim (Inst)
Research Funding - Lilly (Inst); Taiho Oncology (Inst)